UK healthtech startup Zeus Sleep has secured a £150,000 investment from British Design Fund to help accelerate the development of its groundbreaking solutions designed to alleviate the symptoms of snoring and sleep apnoea.
The startup is on a mission to improve the sleep quality of one million people over the next decade.
Chronic snoring is thought to affect nearly a quarter of adults and can lead to health issues, fatigue, and strained relationships.
Traditional treatments for sleep disorders can be intrusive, uncomfortable, and costly, and there are also a plethora of ineffective products on the market.
However, Zeus Sleep is founded by experts in medical technology and engineering and has worked closely with Guy’s & St Thomas’ Hospital, King’s College London, and Morgan Innovation & Technology Ltd.
More than a decade of research has gone into developing Zeus’ devices, which have undergone three clinical trials to validate their effectiveness.
It's developed a wearable device that worn under the chin, employs gentle transcutaneous electrical nerve stimulation (TENS) to stimulate the tongue muscles, thereby helping to keep the airway open during sleep. The non-invasive device aim to address the root causes of disruptive sleep, offering relief to individuals struggling with snoring and sleep apnea and improving the well-being of their partners and families.
Nigel Clarke, CEO of Zeus Sleep, commented:
"We are delighted to have the backing of the British Design Fund. Sleep health profoundly impacts physical and mental wellbeing, and our technology is designed to help individuals and families achieve better rest."
Damon Bonser, CEO of British Design Fund, commented:
“Zeus Sleep is tackling a widespread health challenge with innovative, research-backed solutions that have the potential to transform sleep health globally.
Their commitment to improving wellbeing through cutting-edge technology aligns perfectly with our mission to support pioneering, purpose-led British startups."
The investment will support Zeus Sleep’s expansion. The company plans to launch its first consumer product targeting snoring soon, and pre-orders are already being taken. A medical-grade device aimed at alleviating mild to moderate obstructive sleep apnea is set to follow in 2026.
Lead image: Nigel Clarke, CEO of Zeus Sleep.
Would you like to write the first comment?
Login to post comments